These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31950021)

  • 61. SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells.
    Pan Z; Wang K; Chen Q; Zheng X; Song Z; Ding X
    J Cancer; 2020; 11(2):334-344. PubMed ID: 31897229
    [No Abstract]   [Full Text] [Related]  

  • 62. Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
    Codony-Servat J; García-Roman S; Molina-Vila MÁ; Bertran-Alamillo J; Giménez-Capitán A; Viteri S; Cardona AF; D'Hondt E; Karachaliou N; Rosell R
    J Thorac Oncol; 2018 Sep; 13(9):1324-1337. PubMed ID: 29751136
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway.
    Pan YH; Jiao L; Lin CY; Lu CH; Li L; Chen HY; Wang YB; He Y
    Biologics; 2018; 12():75-86. PubMed ID: 30154647
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
    J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
    [TBL] [Abstract][Full Text] [Related]  

  • 66. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
    Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
    PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.
    Huang Q; Wang Q; Li D; Wei X; Jia Y; Zhang Z; Ai B; Cao X; Guo T; Liao Y
    J Exp Clin Cancer Res; 2019 Mar; 38(1):129. PubMed ID: 30876460
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
    Yu W; Ye F; Yuan X; Ma Y; Mao C; Li X; Li J; Dai C; Qian F; Li J; Fan X; Zhou Y; Wang D; Guo Z; An H; Zhang M; Chen D; Xia S
    BMC Cancer; 2021 Jul; 21(1):877. PubMed ID: 34332557
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors.
    Nakamura R; Fujii H; Yamada T; Matsui Y; Yaoi T; Honda M; Tanaka N; Miyagawa-Hayashino A; Yoshimura A; Morimoto K; Iwasaku M; Tokuda S; Kim YH; Konishi E; Itoh K; Takayama K
    JTO Clin Res Rep; 2023 Jun; 4(6):100525. PubMed ID: 37426308
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeting AXL in NSCLC.
    Zaman A; Bivona TG
    Lung Cancer (Auckl); 2021; 12():67-79. PubMed ID: 34408519
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors.
    Fang F; Dai Y; Wang H; Ji Y; Liang X; Peng X; Li J; Zhao Y; Li C; Wang D; Li Y; Zhang D; Zhang D; Geng M; Liu H; Ai J; Zhou Y
    Acta Pharm Sin B; 2023 Dec; 13(12):4918-4933. PubMed ID: 38045061
    [TBL] [Abstract][Full Text] [Related]  

  • 72.
    Wang L; An Y; Wei X; Huang X; Tu Y; Qiao L; Zhu W
    J Biomol Struct Dyn; 2023 Sep; ():1-13. PubMed ID: 37691424
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Structure-based discovery of potent inhibitors of Axl: design, synthesis, and biological evaluation.
    Wu S; Liao M; Li M; Sun M; Xi N; Zeng Y
    RSC Med Chem; 2022 Oct; 13(10):1246-1264. PubMed ID: 36325401
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The role of salvage surgery in the treatment of a gefitinib-resistant non-small cell lung cancer patient: a case report.
    Zang J; Horinouchi H; Hanaoka J; Funai K; Sakakura N; Liao H
    J Thorac Dis; 2021 Jul; 13(7):4554-4559. PubMed ID: 34422381
    [No Abstract]   [Full Text] [Related]  

  • 75. Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer.
    Huang HN; Hung PF; Chen YP; Lee CH
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338651
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs.
    Li D; Wang J; Liu C; Luo Y; Xu H; Wang Y; Sun N; He J
    Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189759
    [TBL] [Abstract][Full Text] [Related]  

  • 77. miR-613 suppresses renal cell carcinoma proliferation, invasion and migration by regulating the AXL/AKT pathway.
    Duan W; Pan S; Zhai Y; Deng Q; Ren W; Du C; Sun Y
    Exp Biol Med (Maywood); 2023 Feb; 248(4):281-292. PubMed ID: 36852468
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Research Status of Mouse Models for Non-Small-Cell Lung Cancer (NSCLC) and Antitumor Therapy of Traditional Chinese Medicine (TCM) in Mouse Models.
    Chen H; Zheng M; Zhang W; Long Y; Xu Y; Yuan M
    Evid Based Complement Alternat Med; 2022; 2022():6404853. PubMed ID: 36185084
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Yuanhuacin and Related Anti-Inflammatory and Anticancer Daphnane Diterpenes from Genkwa Flos-An Overview.
    Bailly C
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204693
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer.
    Xu C; Zhang L; Wang D; Jiang S; Cao D; Zhao Z; Huang M; Jin J
    Cell Death Discov; 2021 Nov; 7(1):353. PubMed ID: 34775471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.